Eton Pharma announces PKU GOLIKE trial shows statistically significant metabolic control improvement

Eton Pharmaceuticals, Inc.

PKU GOLIKE showed statistically significant reduction in blood Phe (P=0.0002) and increase in Tyr (P=0.0113) vs standard substitutes during overnight fasting.
Average 17.8% reduction in Phe (P=0.0484) and 33.8% increase in Tyr (P=0.0008) from baseline with PKU GOLIKE; standard substitutes led to 27.6% Phe increase.
Study was randomized crossover in pediatric classical PKU patients at Birmingham Children's Hospital; results to be presented at ACMG 2025.
Eton expects data to promote adoption of PKU GOLIKE; product is marketed via existing metabolic sales force.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.